New drug HXN6005 put to the test in healthy volunteers
Knowledge-focused
Recruiting now
This early-stage study is testing a new drug called HXN6005 in 32 healthy adults aged 18 to 55. Participants receive a single dose of either HXN6005 or a placebo, then are monitored for side effects and how the drug moves through the body. The goal is to check safety and tolerabi…
Phase: PHASE1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC